Neurizon Therapeutics Limited (NUZ, formerly PharmAust Limited) is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs. It develops its own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections and provides specialised medicinal and synthetic chemistry services on a contract basis to clients.